Introduction
Allogeneic hematopoietic cell transplantation (HCT) is an effective and therefore indispensable therapy for myeloid malignancies including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) 1 . Cord blood transplantation (CBT), which was first performed approximately 25 years ago 2 , has been technically improved all over the world, and is now as safe and effective as bone marrow or mobilized peripheral blood stem cell transplantation 3 . CBT has been increasingly used as a stem-cell source for allogeneic HCT for myeloid malignancies 2 .
Meanwhile, various conditioning regimens have been developed. The combination of cyclophosphamide (CY; 60 mg/kg for two days) with total body irradiation (TBI; 10 -12 Gy divided into 4 -6 fractions) (CY/TBI regimen), and intravenous busulfan (BU) with CY (BU/CY reigmen)
are the conventional myeloablative regimens in CBT 2, 4 , as well as in bone marrow or peripheral blood stem cell transplantation 5, 6 . Moreover, regimens harboring stronger anti-leukemic effects without increased adverse effects have been quested especially for those with recurrent or refractory AML/MDS in order to reduce post-transplant relapse 2 .
Among these intensified regimens, addition of high-dose cytarabine (HDCA; total dose of 6 -12 g/m 2 ) to the conventional CY/TBI regimen can be a promising strategy, because cytarabine (CA) has long been used as an effective agent during induction and consolidation therapy of AML/MDS 7 .
In previous smaller studies including CBT for leukemia, the HDCA/CY/TBI regimen was reportedly related to a low incidence of relapse and a fair prognosis 3, 8, 9 , while comparison with CY/TBI have not been fully reported. On the other hand, in studies of bone marrow transplantation, this regimen resulted in increased non-relapse mortality (NRM) and inferior OS, compared with that of the conventional CY/TBI regimen 10, 11 . With respect to the rationale for adding HDCA in CBT, there is only limited evidence to inform decisions on whether to add HDCA or not.
Therefore, we performed a cohort study to compare the prognosis in patients who underwent CBT after the HDCA/CY/TBI regimen with that in patients receiving the CY/TBI regimen using the Japanese transplant registry database, with respect to OS, NRM, incidence of relapse, and
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Patients and Methods

Inclusion and exclusion criteria
Written informed consent was obtained from each patient at each institution.
Data collection and definition of each covariate
From the registry database, we extracted data on basic pre-transplant characteristics and post-transplant clinical courses. Patients were categorized into two groups with respect to age (under 50 years of age vs. 50 years or over), performance status (PS; 0 -1 vs. 2 -), and hematopoietic cell transplant commodity index (HCT-CI; 0 -2 vs. 3 -) 13 . With respect to disease risk, the standard-risk was defined as AML in complete remission or MDS in the phase of refractory anemia, ringed sideroblasts, or refractory cytopenia with multilineage dysplasia on the day of transplantation according to the criteria modified from that in the previous study 14 ; other disease types were treated
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shorter or older vs. newer than the median. HLA disparity in HLA-A, B, and DR antigens was determined at the serologic level; 6/6 match was categorized as HLA-matched group, and 5/6 and 4/6 as mismatched group 4 .
With respect to post-transplant clinical courses, engraftment of neutrophils and platelets was defined as the first day of three consecutive days during which neutrophil and platelet counts were at least 500/μL and 2.0 or 5. (Table 1) We evaluated 929 patients aged 16 - Table 1 and Supplemental Tables 1 -2 ; patients with good PS or high-risk disease (particularly those with AML) were conditioned more frequently with HDCA/CY/TBI. GVHD prophylaxis was composed of cyclosporine-and tacrolimus-based regimens, and both were coupled with short-term methotrexate (95.6% and 81.9%, respectively) or mycophenolate mofetil administration (0.9% and 8.1%, respectively). Proportion of cyclosporine-based GVHD prophylaxis was significantly higher in the HDCA/CY/TBI group. Anti-thymocyte globulin was not used in our cohort. Other variables such as sex, age, HCT-CI, disease type (AML or MDS), pre-transplant therapy period, sex mismatch, nuclear cell count of grafts, and year of CBT (before or after 2007) showed no significant differences between these two groups.
Results
Patient characteristics
HDCA improves OS and reduces relapse without augmentation of NRM
OS of the HDCA/CY/TBI group was superior to that of the CY/TBI group ( Figure 1A ; 63.6% vs.
51.9% at 1 year; 53.0% vs. 41.3% at 3 years after CBT). This difference was significant in the univariate analysis (Supplemental Table 3 ; hazard ratio [HR] of overall mortality in the HDCA/CY/TBI group compared to the CY/TBI group, 0.72; 95%CI 0.60 -0.86; p < 0.01). Among other variables, male patients, older age (50 or over), poor PS (2 or more), CMV sero-positivity, and high-risk disease were associated with poorer survival (p < 0.05), while longer pre-transplant therapy period (over 200 days), HLA mismatch, and ABO minor mismatch were in associated with better survival with borderline significance in univariate analyses (p < 0.1; Supplemental Table 3 ). In the multivariate analysis including these factors, the CA/CY/TBI group showed a significantly lower overall mortality than the CY/TBI group (HR, 0.56; 95%CI, 0.45 -0.69; p < 0.01; Table 2 ). This 
Effects of HDCA on post-CBT clinical course
In order to compare the clinical courses that lead to the differences in survival and relapse, we focused on engraftment, GVHD, and infection in each group.
Granulocyte-or macrophage-colony stimulating factors (G-CSF or M-CSF) were used in most of the patients (95.5% in CY/TBI and 97.1% in HDCA/CY/TBI) after CBT, and the HDCA/CY/TBI group showed a significantly higher proportion of neutrophil and platelet engraftment following CBT (Figure 3 ). Complete chimerism was achieved in 83.9% (CY/TBI) and 95.3% (HDCA/CY/TBI; p < 0.01) of those who lived longer than 100 days after CBT. Grade II -IV aGVHD was significantly more often observed in the HDCA/CY/TBI group, while grade III -IV aGVHD differed without significance. The incidence of cGVHD was significantly higher in the HDCA/CY/TBI group ( Figure   3 ). This trend of a higher incidence of GVHD in HDCA/CY/TBI was also confirmed in subgroup analyses for GVHD prophylaxis (cyclosporine-and tacrolimus-based) and HLA mismatch (matched and mismatched) (data not shown). With respect to infectious episodes, no significant differences were observed between the two groups ( Figure 3 ).
The causes of NRM were also compared ( Table 3 ). The major causes of NRM included For
Discussion
The present cohort study regarding addition of HDCA to the conventional CY/TBI regimen in myeloablative CBT for AML/MDS revealed three major findings: (1) the HDCA/CY/TBI regimen improved OS mainly through a reduction in relapse and tumor-related mortality; (2) addition of HDCA did not lead to an increase in the incidence of severe adverse events after CBT or NRM; and Second, we clearly showed that the adverse events in HDCA/CY/TBI are similar to those for CY/TBI with respect to type and incidence. Whether the NRM increases or not by the addition of HDCA has long been a matter of debate; controversial reports 8,10,11,29-35 have been published including various donor sources. Thus, our study, for the first time, revealed the same incidence of NRM following CBT, which can be a strong evidence justifying CBT for AML/MDS with the conditioning regimen of HDCA/CY/TBI.
The causes of NRM were compared between two groups, and no lethal adverse events specific to HDCA/CY/TBI were found. Moreover, infectious episodes were analyzed in detail, and we found
For personal use only. on April 20, 2017. by guest www.bloodjournal.org From that no infections due to bacteria, fungi, or virus increased even after the HDCA/CY/TBI regimen ( Figure 3) . These results are different from previous reports showing a higher incidence of infection and NRM 10, 11 . The discrepancy between studies may be attributed partly to the progress in supportive therapies, such as antibiotics, during this decade. A higher incidence of engraftment in the HDCA/CY/TBI group may also contribute to a reduction in severe infections, particularly in the acute phase following CBT. With respect to the other adverse effects unique to HDCA, such as encephalopathy, retinitis, mucositis, or hepatotoxicity 22 , our database unfortunately lacks these types of data. Other reports showed that these symptoms were commonly observed in the HDCA/CY/TBI regimen, although they were self-limiting and well-managed 30, 33 , which support the feasibility of this regimen in myeloablative transplantation.
In terms of the adverse events, statistical analyses showed that male patient and HLA match are associated with poor prognosis (Table 2 and Supplemental Table 3 ). Higher overall mortality and NRM in male patients were found in the whole cohort and in each arm of the conditioning regimens (data not shown). These data can be explained by the significantly higher proportion of male in the older patients (p < 0.01), or slightly higher mortality in CBT from female donor to male recipient (Supplemental Table 3 The relationship between dosage ("high-dose" CA) and prognosis is also a novel finding, comparing the use of 8 g/m 2 and 12 g/m 2 in our cohort. Dosage selection was subject to each attending physician, and 12 g/m 2 was often used for high-risk disease, younger, or better PS patients, though the difference was not statistically significant (Supplemental Table 4 ). ) was used in some previous reports but was not selected for use in our cohort.
The combination of G-CSF with HDCA is another important topic; it is hypothesized that G-CSF increases the susceptibility of myeloid leukemic cells to HDCA
40
. In a previous report, CBT for myeloid malignancies with G-CSF-combined HDCA/CY/TBI provided low NRM (15% at 3 years) and high OS (51% at 3 years) in a multicenter prospective analysis 9 . This regimen may reduce post-transplant relapse in patients with AML/MDS particularly those transplanted in non-remission status 8 . In our cohort, patients with G-CSF-combined HDCA/CY/TBI regimen (N = 146) revealed relatively promising prognosis (OS; 79.2% at 1 year, and 69.1% at 3 years after CBT).
However, we have data on only a part of the cohort concerning G-CSF administration during conditioning regimens, and statistical comparisons to other groups were not carried out. Further analysis will be necessary comparing HDCA/CY/TBI with and without G-CSF combination.
In summary, we found the superiority of HDCA/CY/TBI regimen relative to the conventional CY/TBI regimen in myeloablative CBT for AML/MDS with respect to a lower incidence of relapse and better OS. Adverse effects due to HDCA can be properly managed. Our data should be validated ) than that of the lower dose group (8 g/m 2 ) (68.3% vs. 61.6% at 1 year; 58.3% vs.
50.5% at 3 years); this difference was significant (p = 0.04) after being adjusted for other confounding factors such as patient sex, age, PS, CMV sero-status, disease risk, pre-transplant therapy period, HLA mismatch, and ABO mismatch. In the subgroup analyses according disease risk, (B) higher-dose HDCA significantly showed the better OS in the high-risk group, while (C) not in the standard-risk group.
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